RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema
China‑based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) and Japan’s Santen Pharmaceutical Co., Ltd. confirmed...
China‑based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) and Japan’s Santen Pharmaceutical Co., Ltd. confirmed...
Japan‑based Santen Pharmaceutical Co., Ltd. (TYO: 4536) announced the commercial launch of Tapcom (tafluprost/timolol maleate) in...
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an agreement with Santen China, a...
Japan-based Santen Pharmaceutical Co., Ltd. announced that its novel glaucoma treatment, Tapcom (tafluprost/timolol maleate), has...
Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from the European...
China’s Uni-Bio Science Group (HKG: 0690) announced that a market filing for its generic version...
Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from China’s National...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its market filing for HR19034 eye...
China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical...
Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese...
Japan-based Santen Pharmaceutical Co. has launched the construction of a new plant in Suzhou, Jiangsu...